Tfelt-Hansen P: Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia. 1998, 18: 532-538. 10.1046/j.1468-2982.1998.1808532.x.
Article
CAS
PubMed
Google Scholar
Solomon GD, Cady RK, Klapper JA, Early NL, Saper JR, Ramadan NM: Clinical efficacy and tolerability of 2,5 mg zolmitriptan for the acute treatment of migraine. Neurology. 1997, 49: 1219-1225.
Article
CAS
PubMed
Google Scholar
Gobel G, Boswell D, Winter P, Crisp A: A comparison of the efficacy, safety and tolerability of naratriptan and sumatriptan. Cephalalgia. 1997, 17: 426-29.
Google Scholar
Block GA, Goldstein J, Polis A, Reines SA, Smith ME: Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache. 1998, 38: 764-771. 10.1046/j.1526-4610.1998.3810764.x.
Article
CAS
PubMed
Google Scholar
Ferrari MD: Which Oral Triptan to Choose?. In: Drug Treatment of Migraine and Other Headaches. Mongr Clin Neurosci. Edited by: Diner HC. 2000, Basel: Karger, 17: 216-221.
Chapter
Google Scholar
Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B, Jiang K, Reines S, Block G: Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache. 1998, 38: 281-287. 10.1046/j.1526-4610.1998.3804281.x.
Article
CAS
PubMed
Google Scholar
Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W, Block GA, Reines SA, Visser WH: Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine. Headache. 1998, 38: 748-755. 10.1046/j.1526-4610.1998.3810748.x.
Article
CAS
PubMed
Google Scholar
Gobel H, Petersen-Braun M, Heinze A: Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders?. In: Frontiers in Headache Research. Headache Treatment: Trial Methodology and New Drugs. Edited by: Olesen J, Tfelt-Hansen P. 1997, Philadelphia: Lippincott-Raven, 6: 93-97.
Google Scholar
Lipton RB, Stewart WF: Acute migraine therapy: Do doctors understand what patients with migraine want from therapy?. Headache. 1999, 39 (suppl 2): S20-S26. 10.1111/j.1526-4610.1999.00006.x.
Article
Google Scholar
Limmroth V, Przywara S: In: Drug Treatment of Migraine and Other Headaches. Mongr Clin Neurosci. Edited by: Diner HC. 2000, Basel: Karger, 17: 30-43.
Chapter
Google Scholar
Krymchantowski AV, Barbosa JS, Cheim C, Alves L: Oral lysine clonixinate in the acute treatment of migraine. A double-blind placebo-controlled study. Arq Neuropsiquiatr. 2001, 59 (1): 46-49.
Article
CAS
PubMed
Google Scholar
Tfelt-Hansen P, McEwen J: Nonsteroidal Antiinflammatory Drugs in the Acute Treatment of Migraine. In: The Headaches. Edited by: Olesen J, Tfelt-Hansen P, Welch KMA. 2000, Philadelphia:Lippincott-Raven, 391-397. 2
Google Scholar
Krymchantowski AV, Adriano M, Fernandes D: Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia. 1999, 19: 186-7. 10.1046/j.1468-2982.1999.1903186.x.
Article
CAS
PubMed
Google Scholar
Krymchantowski AV: Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr. 2000, 58 (2-B): 428-430.
Article
CAS
PubMed
Google Scholar
Krymchantowski AV, Barbosa JS: Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia. 2002, 22: 309-312. 10.1046/j.1468-2982.2002.00369.x.
Article
CAS
PubMed
Google Scholar
Masferrer JL, Isakson PC, Seibert K, Cyclooxygenase-2 inhibitors: A new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am. 1996, 25 (2): 363-372.
Article
CAS
PubMed
Google Scholar
Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999, 282: 1929-1933. 10.1001/jama.282.20.1929.
Article
CAS
PubMed
Google Scholar
Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders. Cephalalgia. 2004, 24: 24-36.
Article
Google Scholar
Ferrari MD, Goadsby PJ, Room KI, Lipton RB: Triptans (Serotonin, 5HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002, 22 (8): 633-58. 10.1046/j.1468-2982.2002.00404.x.
Article
CAS
PubMed
Google Scholar
Silberstein S, Tepper S, Brandes J, Diamond M, Goldstein J, Winner P, Venkatraman S, Vrijens F, Malbecq W, Visser W, Reines S, Yuen E: A randomized, double-blind, placebo-controlled study of Rofecoxib 25 and 50 mg for the acute treatment of migraine. Neurology. 2003, 60 (suppl 1): A337 Abstract-
Google Scholar
Hakkarainen H, Vapaatalo H, Gothoni G, Parantainen J: Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet. 1979, 2: 326-328. 10.1016/S0140-6736(79)90343-X.
Article
CAS
PubMed
Google Scholar
Parantainen J, Vapaatalo H, Hokkanen E: Clinical aspects of prostaglandins and leukotrienes (LT) in migraine. Cephalalgia. 1986, 6 (suppl 4): 95-101.
PubMed
Google Scholar
Sheftell F, Rapoport A, Weeks R, et al: Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache. 2000, 40: 158-63. 10.1046/j.1526-4610.2000.00022.x.
Article
CAS
PubMed
Google Scholar
Saag K, Van Der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, et al: Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs. Arch Fam Med. 2000, 9 (10): 1124-34. 10.1001/archfami.9.10.1124.
Article
CAS
PubMed
Google Scholar
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, for the VIGOR study group, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with reumathoid arthritis. N Eng J Med. 2000, 343: 1520-8. 10.1056/NEJM200011233432103.
Article
CAS
Google Scholar
Mannix L, Von Seggern RL, Adelman JU: Rofecoxib for prevention of menstrual migraine: An open-label study. Neurology. 2003, 60 (suppl 1): A405 Abstract-
Google Scholar
Myllyla V, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J, Vapaatalo H, Eskerod O: Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache. 1998, 38: 201-7. 10.1046/j.1526-4610.1998.3803201.x.
Article
CAS
PubMed
Google Scholar
Bordini CA, Arruda MA, Cicciarelli MC, Speciali JG: Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. A double-blind trial. Arq Neuropsiquiatr. 1997, 55 (3-B): 536-541.
Article
CAS
PubMed
Google Scholar
Peroutka SJ: Beyond monotherapy: Rational polytherapy in migraine. Headache. 1998, 38: 18-22. 10.1046/j.1526-4610.1998.3801018.x.
Article
CAS
PubMed
Google Scholar
Pascual J, Leira R, Lainez JM: Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus Valproate in 52 resistant migraine patients. Headache. 2003, 43: 586 Abstract-
Google Scholar